Answers are grounded in this paper and cite their sources.
A survey reveals varied perceptions of PERT products among healthcare providers, indicating potential barriers to treatment access.
HCPs consider multiple factors when prescribing PERT for patients with EPI. HCP perceptions varied across PERT products, and Creon was favorably perceived more often compared to the other therapeutic options. Various factors may contribute to barriers to treatment and should be addressed to improve access.
No takes yet. Share an insight, caveat, or question.
Ashkar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: